Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443443 · ClinicalTrials.gov registry record
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 1,026
- Enrollment target
NCT00443443 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 1,026 participants.
The verdict
NCT00443443 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 1,026 participants
- Enrollment target
Study Summary
This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no protocol mandated treatment assignment in this study. Patients will be evaluated and treated according to their physician's standard practice and discretion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,026 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00443443
The ClinicalTrials.gov registry entry for NCT00443443 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,026 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00443443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00443443 about?
NCT00443443 is a clinical study titled "A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)". This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will recei...
What is the current status of trial NCT00443443?
This trial is currently completed. The enrollment target is 1,026 participants. The study started on 2007-01. Estimated completion is 2013-09.
Who is sponsoring clinical trial NCT00443443?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.